Swiss National Bank takes new $1.4M stake in Urogen Pharma
What's the deal? The Swiss National BankDealroom has a profile for this one. Try Dealroom → bought a new position in Urogen Pharma during the first quarter of 2026, acquiring 77,800 shares worth about $1,399,000. That gives it roughly 0.16% of the biopharmaceutical company, per its latest disclosure with the Securities and Exchange Commission.
Why it matters: The move adds to heavy institutional ownership of Urogen, which stands at 91.29% of the stock. Hedge funds and large investors continue to reshape their holdings around the company.
Zoom in: Paradigm Biocapital Advisors raised its stake 6.1% to 4,473,648 shares worth $104,773,000. Morgan StanleyDealroom has a profile for this one. Try Dealroom → grew its holding 1.4% to 2,562,901 shares valued at $60,023,000, while Soleus Capital Management opened a new position worth $29,934,000.
Yes, but: Insiders have been selling. Mark Schoenberg sold 10,000 shares at $40.00 each on July 9, 2026, US$258.8K transaction under a pre-arranged Rule 10b5-1 trading plan. Insiders offloaded 25,222 shares worth $892,661 in the three months to July 2026.
The state of play: Urogen stock traded around $38.24 in early August 2026, down 6.9% on the session, against a 12-month range of $15.86 to $43.93. The company carries a market capitalisation of $1.86 billion and a negative price-to-earnings ratio of -13.91.
By the numbers: Analysts hold a "Moderate Buy" consensus with an average price target of $41.62. One rates the stock "Strong Buy," seven "Buy," one "Hold," and one "Sell." OppenheimerDealroom has a profile for this one. Try Dealroom → lifted its target to $50.00, while Weiss Ratings reiterated a "sell (d-)."
The signal: Central banks and pension funds accumulating positions in a loss-making biopharma company underscore continued institutional appetite for the sector — even as insiders trim and analysts split on where the stock goes next.
Read more: Ticker Report
Image credit: Generated with Gemini
